<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Biochem</journal-id><journal-title>BMC Biochemistry</journal-title><issn pub-type="epub">1471-2091</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2106361</article-id><article-id pub-id-type="pmid">18047734</article-id><article-id pub-id-type="publisher-id">1471-2091-8-S1-S10</article-id><article-id pub-id-type="doi">10.1186/1471-2091-8-S1-S10</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Fanconi anemia pathway and ubiquitin</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Jacquemont</surname><given-names>C&#x000e9;line</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Taniguchi</surname><given-names>Toshiyasu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ttaniguc@fhcrc.org</email></contrib></contrib-group><aff id="I1"><label>1</label>Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., C1-015, Seattle, WA 98109-1024, USA</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2007</year></pub-date><volume>8</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Ubiquitin-Proteasome System in Disease Part 1</named-content><named-content content-type="supplement-editor">Edited by John Mayer and Rob Layfield</named-content></supplement><fpage>S10</fpage><lpage>S10</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2091/8/S1/S10"/><permissions><copyright-statement>Copyright &#x000a9; 2007 Jacquemont and Taniguchi; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Jacquemont and Taniguchi; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Jacquemont
               C&#x000e9;line
               
            </dc:author><dc:title>
            The Fanconi anemia pathway and ubiquitin
         </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Biochemistry 8(Suppl 1): S10-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2091(2007)8:Suppl 1&#x0003c;S10&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2091</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Fanconi anemia (FA) is a rare genetic disorder characterized by aplastic anemia, cancer/leukemia susceptibility and cellular hypersensitivity to DNA crosslinking agents, such as cisplatin. To date, 12 FA gene products have been identified, which cooperate in a common DNA damage-activated signaling pathway regulating DNA repair (the FA pathway). Eight FA proteins form a nuclear complex harboring E3 ubiquitin ligase activity (the FA core complex) that, in response to DNA damage, mediates the monoubiquitylation of the FA protein FANCD2. Monoubiquitylated FANCD2 colocalizes in nuclear foci with proteins involved in DNA repair, including BRCA1, FANCD1/BRCA2, FANCN/PALB2 and RAD51. All these factors are required for cellular resistance to DNA crosslinking agents. The inactivation of the FA pathway has also been observed in a wide variety of human cancers and is implicated in the sensitivity of cancer cells to DNA crosslinking agents. Drugs that inhibit the FA pathway may be useful chemosensitizers in the treatment of cancer.</p><p><bold>Publication history: </bold>Republished from Current BioData's Targeted Proteins database (TPdb; <ext-link ext-link-type="uri" xlink:href="http://www.targetedproteinsdb.com"/>).</p></abstract></article-meta></front><body><sec><title>Protein pathway in the disease</title><sec><title>Fanconi anemia</title><p>Fanconi anemia (FA) is a rare autosomal or X-linked recessive disease characterized by chromosomal instability and cancer susceptibility. All FA complementation groups (discussed below) except FA-B are inherited autosomally [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. FA prevalence is estimated to be 1&#x02013;5 per million and the frequency of heterozygous carriers to be 1 in 300 [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Notwithstanding the small number of FA patients, this disease constitutes a dynamic research area because the FA pathway plays a crucial role in preventing genomic instability and provides an attractive model for understanding the interplay between DNA repair and ubiquitin biology in tumorigenesis and cancer therapy (reviewed in [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B15">15</xref>]).</p><p>The clinical course and the treatment of FA have been extensively reviewed elsewhere [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. Clinically, FA is characterized by childhood onset aplastic anemia, increased cancer/leukemia susceptibility and developmental defects. Typically, FA patients develop bone marrow failure leading to aplastic anemia during the first decade of life and at least 20% develop malignancies. Most commonly, these include acute myelogenous leukemia and myelodysplastic syndrome, but also head and neck squamous cell carcinoma, gynecological squamous cell carcinoma, esophageal carcinoma, and liver, brain, skin and renal tumors [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. FA subtypes FA-D1 and FA-N are associated with increased predisposition to medulloblastoma, Wilms' tumor and acute leukemia in early childhood, and are clinically different from the other FA subtypes [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. Common developmental defects observed in FA are short stature, developmental disability and abnormalities of the skin, upper extremities, head, eyes, kidneys and ears [<xref ref-type="bibr" rid="B3">3</xref>]. In addition, male FA patients often present abnormal gonads [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>FA cells are hypersensitive to treatment with DNA crosslinking agents such as cisplatin, mitomycin C (MMC), melphalan and diepoxybutane [<xref ref-type="bibr" rid="B25">25</xref>], leading to increased chromosome breakage [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec><title>The Fanconi anemia pathway</title><sec><title>Proteins involved in the Fanconi anemia pathway</title><p>FA can be divided into at least thirteen complementation groups (FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M and -N), of which the responsible genes for all groups except FA-I have been identified (summarized in Table <xref ref-type="table" rid="T1">1</xref>) [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. All FA proteins are required for cellular resistance to DNA crosslinking agents [<xref ref-type="bibr" rid="B6">6</xref>] and are considered to cooperate in a common pathway (the FA pathway) that regulates the sensing, signaling and/or repair of interstrand DNA crosslinks (Figure <xref ref-type="fig" rid="F1">1</xref>). FA proteins are closely related to the breast/ovarian cancer susceptibility genes products BRCA1 and BRCA2, and to their partner proteins, as described below. <italic>FANCD1</italic> (mutated in FA-D1) is identical to <italic>BRCA2</italic>[<xref ref-type="bibr" rid="B31">31</xref>] and the most recently identified FA gene, <italic>FANCN,</italic> is in fact <italic>PALB2</italic> (<underline>p</underline>artner <underline>a</underline>nd <underline>l</underline>ocalizer of <underline>B</underline>RCA2) [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], a crucial regulator of the BRCA2 protein [<xref ref-type="bibr" rid="B32">32</xref>]. Additionally, <italic>FANCJ</italic> is identical to <italic>BACH1/BRIP1</italic>[<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B33">33</xref>], a DNA helicase that interacts directly with BRCA1. Furthermore, FANCD2, FANCD1/BRCA2, FANCN/PALB2 and BRCA1 colocalize in nuclear foci at the site of DNA damage [<xref ref-type="bibr" rid="B32">32</xref>][<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>] and BRCA1 itself is required for efficient nuclear foci formation of FANCD2 [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. In light of these interplays between FA and BRCA proteins, the FA pathway is also called the &#x0201c;FA-BRCA pathway&#x0201d; [<xref ref-type="bibr" rid="B5">5</xref>] or &#x0201c;FA-BRCA network&#x0201d; [<xref ref-type="bibr" rid="B11">11</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The responsible genes for Fanconi anemia</p></caption><table frame="hsides" rules="groups"><thead><tr><td>Subtype</td><td>Responsible gene</td><td>Protein (kDa)</td><td>Requirement for FANCD2 monoubiquitylation</td><td>Function of the protein, etc.</td><td colspan="7">Homologs in</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="7"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><bold>Yeast</bold></td><td><bold>Plant</bold></td><td><bold>Fly</bold></td><td><bold>Worm</bold></td><td><bold>Fish</bold></td><td><bold>Amphibian</bold></td><td><bold>Human, mouse, chicken</bold></td></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td></td><td><italic>S. cerevisiae</italic></td><td><italic>A. thaliana</italic></td><td><italic>D. melanogaster</italic></td><td><italic>C. elegans</italic></td><td><italic>D. rerio</italic></td><td><italic>X. laevis</italic></td><td></td></tr><tr><td>A</td><td><italic>FANCA</italic></td><td>163</td><td>+</td><td>FA core complex</td><td></td><td></td><td></td><td></td><td>+ [123]</td><td>+ [124]</td><td>+</td></tr><tr><td>B</td><td><italic>FANCB</italic></td><td>95</td><td>+</td><td>FA core complex</td><td></td><td></td><td></td><td></td><td>+ [123]</td><td>+ [124]</td><td>+</td></tr><tr><td>C</td><td><italic>FANCC</italic></td><td>63</td><td>+</td><td>FA core complex</td><td></td><td></td><td></td><td></td><td>+ [123]</td><td>+ [124]</td><td>+</td></tr><tr><td>D1</td><td><italic>FANCD1/BRCA2</italic></td><td>380</td><td>-</td><td>RAD51 recruitment</td><td></td><td></td><td></td><td>+ [135]</td><td>+ [123]</td><td>+ [124]</td><td>+</td></tr><tr><td>D2</td><td><italic>FANCD2</italic></td><td>155,162</td><td>+</td><td>monoubiquitylated protein</td><td></td><td>+ [133]</td><td>+ [27,125]</td><td>+ [126]</td><td>+ [123,127]</td><td>+ [124]</td><td>+</td></tr><tr><td>E</td><td><italic>FANCE</italic></td><td>60</td><td>+</td><td>FA core complex</td><td></td><td></td><td></td><td></td><td>+ [123]</td><td>+ [124]</td><td>+</td></tr><tr><td>F</td><td><italic>FANCF</italic></td><td>42</td><td>+</td><td>FA core complex</td><td></td><td></td><td></td><td></td><td>+ [123]</td><td>+ [136]</td><td>+</td></tr><tr><td>G</td><td><italic>FANCG/XRCC9</italic></td><td>68</td><td>+</td><td>FA core complex</td><td></td><td></td><td></td><td></td><td>+ [123]</td><td>+ [124]</td><td>+</td></tr><tr><td>I</td><td>not identified</td><td>?</td><td>+</td><td>?</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>J</td><td><italic>FANCJ/BACH1/BRIP1</italic></td><td>130</td><td>-</td><td>5&#x02032;&#x02192;3&#x02032; DNA helicase/ATPase</td><td>+ [132]</td><td></td><td></td><td>+ [126]</td><td></td><td></td><td>+</td></tr><tr><td>L</td><td><italic>FANCL/PHF9/POG</italic></td><td>43</td><td>+</td><td>FA core complex, E3 ubiquitin ligase</td><td></td><td>+ [134]</td><td>+ [27,125]</td><td></td><td>+ [123]</td><td>+ [124]</td><td>+</td></tr><tr><td>M</td><td><italic>FANCM/Hef</italic></td><td>250</td><td>+</td><td>FA core complex, ATPase/translocase, DNA helicase motifs</td><td>+ [27]</td><td></td><td>+ [125]</td><td>+ [126]</td><td></td><td></td><td>+</td></tr><tr><td>N</td><td><italic>FANCN/PALB2</italic></td><td>130</td><td>-</td><td>regulation of BRCA2 localization</td><td></td><td></td><td></td><td></td><td>+</td><td>+</td><td>+</td></tr></tbody></table><table-wrap-foot><p>(Adapted with modifications from &#x0201c;The molecular pathogenesis of Fanconi anemia: recent progress&#x0201d; Taniguchi T and D'Andrea AD. Blood, Jun 2006; 107: 4223&#x02013;4233. [6])</p><p>FANC protein homologs shown in the table are limited to the ones reported in the literature [27,123&#x02013;127,132&#x02013;136].</p></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Current model of the Fanconi anemia pathway</bold>. (Adapted with modifications from &#x0201c;The molecular pathogenesis of Fanconi anemia: recent progress&#x0201d; Taniguchi T and D'Andrea AD. Blood, Jun 2006; 107: 4223 &#x02013; 4233. [<xref ref-type="bibr" rid="B6">6</xref>]) Eight FA proteins (FANC-A, -B, -C, -E, -F, -G, -L and -M), a FANCM-interacting protein called FAAP24 and an unidentified factor (FAAP100) form a nuclear complex (the FA core complex) with E3 ubiquitin ligase activity. FANCL is the catalytic subunit of the complex and directly interacts with the E2 ubiquitin conjugating enzyme UBE2T through its PHD/RING domain. UBE2T can be inactivated by auto-monoubiquitylation on lysine 91 (K91), but is suggested to form a thioester intermediate with ubiquitin through it's catalytic cysteine 86 (C86) when taking part in the ubiquitylation of FANCD2 (see below). The FA core complex, BLM, RPA and topoisomerase III&#x003b1; form a larger super-complex called BRAFT. Note that for diagrammatic purposes the FA core complex is shown here interacting with the FAAP100 subunit, but in reality the quaternary structure of the BRAFT complex is unknown. In response to exogenous DNA damage, or during normal S phase progression, the FANCD2 protein is monoubiquitylated on lysine 561 (K561) in an FA core complex- and UBE2T-dependent manner. DNA damage-induced monoubiquitylation of FANCD2 also requires ATR and RPA. Monoubiquitylation of FANCD2 targets the protein into nuclear foci where it co-localizes with BRCA1, FANCD1/BRCA2, FANCN/PALB2, RAD51, FANCJ/BRIP1 and other proteins. At least some components of the FA core complex (FANCC, FANCE and FANCG) also form nuclear foci. All of these factors are required for cellular resistance to DNA crosslinking agents. Monoubiquitylation of PCNA on lysine 164 (K164) requires RAD6 as an E2 and RAD18 as an E3, but not the FA core complex. In turn, modification of PCNA causes recruitment of translesion synthesis (TLS) DNA polymerases at the site of stalled replication forks. USP1 deubiquitylates both PCNA and FANCD2, negatively regulating both the Fanconi anemia pathway and monoubiquitylation of PCNA.</p></caption><graphic xlink:href="1471-2091-8-S1-S10-1"/></fig></sec><sec><title>The FA core complex and monoubiquitylation of FANCD2</title><p>Ubiquitin plays a crucial role in the regulation of the FA pathway. Eight FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and FANCM), a newly identified FANCM-interacting protein called FAAP24 (<underline>FA</underline>NCA-<underline>a</underline>ssociated <underline>p</underline>olypeptide) [<xref ref-type="bibr" rid="B137">137</xref>] and an unidentified factor called FAAP100 form a nuclear protein complex (the FA core complex) required for monoubiquitylation of FANCD2 on lysine 561 [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. One of the components of the FA core complex, FANCL, has a PHD (plant homeodomain) finger/RING finger domain exhibiting auto-ubiquitin ligase activity <italic>in vitro</italic>[<xref ref-type="bibr" rid="B38">38</xref>][<xref ref-type="bibr" rid="B39">39</xref>-<xref ref-type="bibr" rid="B41">41</xref>]. FANCL associates through its PHD/RING finger domain with UBE2T, a ubiquitin conjugating enzyme (E2), which is also required for <italic>in vivo</italic> FANCD2 monoubiquitylation [<xref ref-type="bibr" rid="B42">42</xref>]. Taken together, the FA core complex is assumed to constitute a multi-subunit E3 ubiquitin ligase complex for FANCD2, in which FANCL is the catalytic E3 ubiquitin ligase subunit. The catalytic activity of this complex appears to be regulated through the inhibitory auto-monoubiquitylation of UBE2T, stimulated in the presence of FANCL [<xref ref-type="bibr" rid="B42">42</xref>]. However, as the direct monoubiquitylation of FANCD2 by the FA core complex has not been reconstituted so far <italic>in vitro</italic>, the existence of other E2 and E3 enzymes responsible for FANCD2 monoubiquitylation (and somehow controlled by the FA core complex, the E2 activity of UBE2T and the E3 activity of FANCL) cannot be ruled out formally.</p><p>Even though a direct DNA binding activity has been demonstrated for unmodified FANCD2 <italic>in vitro</italic>[<xref ref-type="bibr" rid="B43">43</xref>], monoubiquitylation of the protein is required for its translocation to chromatin <italic>in vivo</italic> and nuclear foci formation at the site of DNA damage, as well as for cellular resistance to DNA crosslinking agents [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. FANCD2 monoubiquitylation and nuclear foci formation occur in response to DNA damaging agents (ionizing radiation, UV light irradiation, DNA crosslinking agents, hydroxyurea, etc.) and during S phase of the cell cycle even in the absence of exogenous DNA damage [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. A DNA damage-activated signaling kinase, ATR, and a single-strand DNA binding protein complex, RPA, are required for DNA damage-inducible monoubiquitylation and foci formation of FANCD2, indicating an upstream role for these factors in the activation of the FA pathway [<xref ref-type="bibr" rid="B46">46</xref>]. The exact signal and activation cascade required for FANCD2 monoubiquitylation, however, remain elusive. The existence of a specific FANCD2 receptor responsible for recruitment of the monoubiquitylated protein to chromatin has also been proposed [<xref ref-type="bibr" rid="B44">44</xref>], but not demonstrated to date.</p></sec><sec><title>Roles for the FA core complex in DNA enzymatic processing</title><p>The FA core complex is not simply the ubiquitin ligase complex for FANCD2. In addition to its requirement for FANCD2 monoubiquitylation, the FA core complex is required for the translocation into chromatin of monoubiquitylated FANCD2, and for cellular resistance to interstrand DNA crosslinks even if FANCD2 is localized in chromatin, as elegantly demonstrated in chicken DT40 cells using FANCD2&#x02013;monoubiquitin and FANCD2&#x02013;histone H2B chimeric proteins [<xref ref-type="bibr" rid="B47">47</xref>]. In addition, one component of the FA core complex, FANCM, harbors DNA helicase motifs, a degenerate nuclease motif and <italic>in vitro</italic> DNA-stimulated ATPase and translocase activities [<xref ref-type="bibr" rid="B27">27</xref>]. The newly identified FAAP24 protein, in complex with FANCM, has been shown to preferentially bind to ssDNA and branched DNA structures [<xref ref-type="bibr" rid="B137">137</xref>]. Speculatively, FANCM DNA translocase activity could play an important role in displacing the FA core complex along the DNA, allowing DNA damage recognition, or FAAP24 specificity for ssDNA structures may target FANCM and the FA core complex to abnormal, branched DNA structures. In summary, the FA core complex itself can interact with DNA and displays some important functions outside of FANCD2 monoubiquitylation.</p><p>Furthermore, the FA core complex forms a larger complex with BLM, RPA and topoisomerase III&#x003b1; called BRAFT (for <underline>B</underline>LM, <underline>R</underline>P<underline>A</underline>, <underline>F</underline>A, and <underline>t</underline>opoisomerase III&#x003b1;). Although the functional relevance of BRAFT is not clear, it harbors a DNA unwinding activity potentially relevant for DNA repair [<xref ref-type="bibr" rid="B37">37</xref>].</p></sec><sec><title>Negative regulation of the Fanconi anemia pathway by FANCD2 deubiquitylation</title><p>FANCD2 monoubiquitylation is a regulated and reversible process. USP1, a deubiquitylating enzyme, removes ubiquitin from monoubiquitylated FANCD2, therefore negatively regulating the FA pathway [<xref ref-type="bibr" rid="B48">48</xref>]. Interestingly, USP1 also deubiquitylates monoubiquitylated PCNA (<underline>p</underline>roliferating <underline>c</underline>ell <underline>n</underline>uclear <underline>a</underline>ntigen), a DNA polymerase processivity factor [<xref ref-type="bibr" rid="B49">49</xref>]. PCNA monoubiquitylation leads to the switch from a replicative polymerase to a translesion synthesis (TLS) polymerase at the site of stalled replication forks [<xref ref-type="bibr" rid="B50">50</xref>] and participates in the bypass of DNA lesion. Monoubiquitylation of PCNA is dependent on RAD6 (an E2) and RAD18 (an E3) [<xref ref-type="bibr" rid="B51">51</xref>], but is independent of the FA core complex. Therefore, these two pathways (the FA pathway and TLS activation through PCNA monoubiquitylation) have different activation mechanisms, but share a common shutoff mechanism.</p></sec><sec><title>The Fanconi anemia pathway and DNA repair</title><p>Interestingly, some TLS polymerases are also implicated in cellular resistance to interstrand DNA crosslinks [<xref ref-type="bibr" rid="B52">52</xref>]. For example, mutations in TLS polymerase-encoding <italic>REV3</italic> or <italic>REV1</italic> have been shown to be epistatic with <italic>FANCC</italic> mutations for crosslinker hypersensitivity in chicken DT40 cells [<xref ref-type="bibr" rid="B53">53</xref>]. Furthermore, REV1 and FANCD2 colocalize in nuclear foci [<xref ref-type="bibr" rid="B53">53</xref>], which could suggest a possible interaction between them. The possible interplay of FA proteins and TLS polymerases in a common pathway regulating the bypass of DNA damage, however, remains to be clarified.</p><p>One of the most important issues to clarify concerning the role of the FA pathway in DNA repair is how FA proteins (the FA core complex, FANCD2, FANCD1/BRCA2, FANCN/PALB2, FANCJ/BRIP1/BACH1) and other factors (RAD51, BRCA1, BLM, TLS polymerases etc.) cooperate to sense, signal and repair DNA crosslinks.</p><p>In nuclear foci, FANCD2 colocalizes with factors known to be involved in DNA repair and/or DNA damage response, such as BRCA1, FANCD1/BRCA2, FANCN /PALB2, RAD51, BLM, RPA and ATR [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>]. FANCD2 also partially colocalizes with FANCJ/BRIP1/BACH1 [<xref ref-type="bibr" rid="B33">33</xref>] and NBS1, part of the MRE11&#x02013;RAD50&#x02013;NBS1 complex implicated in the recognition and early signalization of damaged DNA [<xref ref-type="bibr" rid="B54">54</xref>]. Among the subunits of the FA core complex, at least FANCC and FANCE are reported to colocalize with FANCD2 in nuclear foci [<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B55">55</xref>], and FANCG with BRCA2 and RAD51 [<xref ref-type="bibr" rid="B56">56</xref>]. All these factors are required for cellular resistance to interstrand DNA crosslinking agents.</p><p>Among FA proteins, FANCD1/BRCA2 and FANCJ/BRIP1/BACH1 are neither part of the FA core complex nor required for FANCD2 monoubiquitylation or foci formation [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. They may work downstream of FANCD2 monoubiquitylation and/or in another pathway. Interestingly, these proteins have been strongly linked to DNA double-strand breaks repair by homologous recombination (HR) [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B57">57</xref>]. Specifically, FANCD1/BRCA2 regulates HR by controlling the activity of RAD51, the eukaryotic homolog of bacterial RecA [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>]. FANCD1/BRCA2 stability and localization in nuclear structures (chromatin and nuclear matrix) is in turn regulated by FANCN/PALB2 [<xref ref-type="bibr" rid="B32">32</xref>]. Whether FANCD1/BRCA2, FANCN/PALB2 and RAD51 act downstream or independently of monoubiquitylated FANCD2 and other FA proteins remains unclear. Evidence in favor of a regulatory role for the FA pathway on FANCD1/BRCA2 and RAD51 function comes from reports that monoubiquitylated FANCD2 is required for both the loading of FANCD1/BRCA2 onto damaged chromatin and the increase in FANCD1/BRCA2 and RAD51 nuclear foci in response to DNA damage [<xref ref-type="bibr" rid="B35">35</xref>]. However, the requirement for the FA core complex and FANCD2 in efficient RAD51 foci formation in response to DNA damage [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B60">60</xref>], as well as the efficiency of HR in FA cells (reviewed in reference [<xref ref-type="bibr" rid="B6">6</xref>]), remain controversial. FANCD1/BRCA2- and FANCN/PALB2-deficient cells have a clear defect in RAD51 foci formation and HR efficiency [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B61">61</xref>-<xref ref-type="bibr" rid="B63">63</xref>]. In other FA cells, at least mild defects in HR have been documented [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B64">64</xref>-<xref ref-type="bibr" rid="B67">67</xref>], although other reports show normal HR efficiency in these cells [<xref ref-type="bibr" rid="B68">68</xref>-<xref ref-type="bibr" rid="B70">70</xref>].</p><p>FANCJ/BRIP1/BACH1 has DNA-dependent ATPase activity and 5&#x02032;&#x02013;3&#x02032; DNA helicase activity, and directly binds to the phospho-protein binding BRCT (<underline>BR</underline>CA1 <underline>c</underline>arboxyl-<underline>t</underline>erminal domain [<xref ref-type="bibr" rid="B72">72</xref>,<xref ref-type="bibr" rid="B73">73</xref>]) of BRCA1 [<xref ref-type="bibr" rid="B71">71</xref>]. How FANCJ/BRIP1/BACH1 interacts with other FA proteins has not been reported, except for partial colocalization with FANCD2 in nuclear foci [<xref ref-type="bibr" rid="B33">33</xref>]. Though RAD51 foci formation is normal in FA-J cells (deficient in FANCJ/BRIP1/BACH1) [<xref ref-type="bibr" rid="B63">63</xref>], HR efficiency appears to be affected [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Taken together, these evidences suggest that FANCD2 plays a role in regulating DNA repair (especially of interstrand DNA crosslinks) in chromatin in cooperation with BRCA1, FANCD1/BRCA2, FANCJ/BRIP1/BACH1, the FA core complex and other factors, but the precise mechanism by which this occurs remains unknown. The highly regulated process of FANCD2 monoubiquitylation could play a crucial role in orienting the repair of DNA damage to HR and/or in attracting TLS polymerases to sites of DNA damage.</p></sec><sec><title>Other roles for the Fanconi anemia proteins outside of DNA repair</title><p>Several FA proteins function outside of DNA crosslink repair. For example, the phosphorylation of FANCD2 at serine 222 by ATM kinase in response to ionizing radiation is required for the establishment of IR-induced intra-S phase checkpoint, but is not required for resistance to DNA crosslinking agents [<xref ref-type="bibr" rid="B74">74</xref>]. Additionally, FANCC (localized in both the cytoplasm and nucleus) is implicated in several cytoplasmic functions, such as JAK/STAT and apoptotic signaling [<xref ref-type="bibr" rid="B75">75</xref>-<xref ref-type="bibr" rid="B80">80</xref>].</p></sec></sec><sec><title>Alterations in the Fanconi anemia pathway in human cancer in the general (non-FA) population</title><p>FA patients have an increased risk of developing leukemia and solid tumors, but alterations in the FA pathway have also been reported in a wide variety of human cancers in the general (non-FA) population [<xref ref-type="bibr" rid="B81">81</xref>-<xref ref-type="bibr" rid="B94">94</xref>] (reviewed in references [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B10">10</xref>]). Abnormalities in <italic>BRCA1</italic> and <italic>BRCA2</italic> in cancer have been reviewed elsewhere [<xref ref-type="bibr" rid="B95">95</xref>]. Methylation of <italic>FANCF</italic>, leading to its decreased expression, has been reported in ovarian cancer [<xref ref-type="bibr" rid="B81">81</xref>,<xref ref-type="bibr" rid="B82">82</xref>], breast cancer [<xref ref-type="bibr" rid="B84">84</xref>], non-small cell lung cancer [<xref ref-type="bibr" rid="B85">85</xref>], cervical cancer [<xref ref-type="bibr" rid="B86">86</xref>], testicular cancer [<xref ref-type="bibr" rid="B87">87</xref>], head and neck squamous cell carcinoma [<xref ref-type="bibr" rid="B85">85</xref>], and granulosa cell tumors of the ovary [<xref ref-type="bibr" rid="B83">83</xref>]. Inherited and somatic mutations of <italic>FANCC</italic> and <italic>FANCG</italic> have been detected in a subset of young onset pancreatic cancer [<xref ref-type="bibr" rid="B89">89</xref>,<xref ref-type="bibr" rid="B96">96</xref>]. Additionally, inherited mono-allelic mutations in <italic>BACH1/BRIP1/FANCJ</italic> and <italic>FANCN/PALB2</italic> have been recently implicated in breast cancer predisposition (familial breast cancer) [<xref ref-type="bibr" rid="B97">97</xref>][<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], suggesting that these genes may be the low penetrance breast/ovarian cancer susceptibility genes researchers have been looking for to explain the non-BRCA1/non-BRCA2 cases. Because the integrity of the FA pathway is crucial for cellular resistance to interstrand DNA crosslinking agents (cisplatin, MMC, melphalan, etc.), tumors with defects in the pathway may be hypersensitive to these agents. In fact, in some cancer cell lines (human ovarian cancer cell lines (TOV-21G and 2008) [<xref ref-type="bibr" rid="B81">81</xref>], human myeloma cell lines (8226 and U266) [<xref ref-type="bibr" rid="B98">98</xref>] and a human pancreatic cancer cell line (PL11) [<xref ref-type="bibr" rid="B99">99</xref>]), the integrity of the FA pathway is a determinant of cisplatin (or melphalan) resistance <italic>in vitro</italic> or <italic>in vivo</italic> (mouse xenograft model) [<xref ref-type="bibr" rid="B81">81</xref>,<xref ref-type="bibr" rid="B98">98</xref>-<xref ref-type="bibr" rid="B100">100</xref>].</p></sec></sec><sec><title>Disease models, knockouts, assays</title><p>Generation of various knockout murine models for FA (<italic>Fanca</italic>[<xref ref-type="bibr" rid="B101">101</xref>,<xref ref-type="bibr" rid="B102">102</xref>]<italic>, Fancc</italic>[<xref ref-type="bibr" rid="B103">103</xref>,<xref ref-type="bibr" rid="B104">104</xref>], <italic>Fancg</italic>[<xref ref-type="bibr" rid="B105">105</xref>,<xref ref-type="bibr" rid="B106">106</xref>], <italic>Fancd2</italic>[<xref ref-type="bibr" rid="B107">107</xref>], <italic>Fanca</italic>-<italic>Fancc</italic> double [<xref ref-type="bibr" rid="B108">108</xref>], <italic>Fancl</italic>/<italic>Pog</italic>[<xref ref-type="bibr" rid="B109">109</xref>] and <italic>Fancd1/Brca2 </italic>[<xref ref-type="bibr" rid="B110">110</xref>] ) have been reported. These FA mice display similar phenotypes to that of human FA patients, for example chromosome instability, defective germ cell development and sensitivity to DNA crosslinking agents. Although FA mice do not spontaneously develop bone marrow failure (except for mouse models of the FA-D1 group, harboring homozygous hypomorphic mutations in <italic>Fancd1/Brca2</italic>[<xref ref-type="bibr" rid="B110">110</xref>]), treatment with MMC causes bone marrow failure in <italic>Fancc</italic> knockout mice [<xref ref-type="bibr" rid="B111">111</xref>]. The reason for the absence of spontaneous bone marrow failure in FA mice is still unknown. Several FA mice (<italic>Fancd2</italic>[<xref ref-type="bibr" rid="B107">107</xref>]<italic>, Fanca</italic>[<xref ref-type="bibr" rid="B102">102</xref>] and <italic>Fancc </italic>[<xref ref-type="bibr" rid="B112">112</xref>]) are reported to develop tumors including adenocarcinoma, lymphoma, sarcoma and ovarian granulosa cell tumor. In addition, many <italic>Brca1-</italic> and <italic>Brca2-</italic>deficient mouse models with cancer susceptibility have been generated (reviewed in reference [<xref ref-type="bibr" rid="B113">113</xref>]). FA mice are useful tools to test the applicability of new FA treatment modalities, such as gene therapy [<xref ref-type="bibr" rid="B114">114</xref>-<xref ref-type="bibr" rid="B120">120</xref>], <italic>ex vivo</italic> manipulation of hematopoietic stem/progenitor cells [<xref ref-type="bibr" rid="B121">121</xref>] and cytokine treatment [<xref ref-type="bibr" rid="B122">122</xref>].</p><p><italic>Drosophila, Caenorhabditis elegans, Xenopus</italic> and zebrafish homologs of FA genes have been more recently identified (Table <xref ref-type="table" rid="T1">1</xref>). The FA gene network is conserved from zebrafish [<xref ref-type="bibr" rid="B123">123</xref>] and <italic>Xenopus</italic>[<xref ref-type="bibr" rid="B124">124</xref>] to human, while only <italic>FANCD2, FANCL</italic> and <italic>FANCM</italic> have <italic>Drosophila</italic> homologs [<xref ref-type="bibr" rid="B125">125</xref>], and <italic>FANCD1/BRCA2, FANCD2 (FCD-2), FANCJ</italic> and <italic>FANCM</italic> have homologs in <italic>C. elegans</italic>[<xref ref-type="bibr" rid="B126">126</xref>] (Table <xref ref-type="table" rid="T1">1</xref>). <italic>Drosophila</italic> and <italic>C. elegans</italic> models will therefore be useful for testing the functions of key proteins in the FA pathway. As only FANCD2, FANCL and FANCM are present in <italic>Drosophila</italic>, these proteins may constitute the minimal FA pathway machinery. In turn, <italic>C. elegans</italic> may enable a better understanding of the roles of FANCD1/BRCA2 and FANCJ in the context of the minimal machinery constituted by FANCD2 and FANCM. As with vertebrate mutants, <italic>Drosophila fancd2</italic> and <italic>fancl</italic> mutants, as well as <italic>C. elegans fancd2</italic> mutants, show hypersensitivity to DNA crosslinking agents [<xref ref-type="bibr" rid="B125">125</xref>,<xref ref-type="bibr" rid="B126">126</xref>]. <italic>Drosophila</italic> and <italic>C. elegans</italic> models may, therefore, be useful to dissect the roles and regulations of the FA pathway in a less complex network. The zebrafish model may prove a valuable tool with which to investigate the impact of FA pathway failure on development as <italic>fancd2</italic>-deficient zebrafish embryos develop similar defects to those found in children with FA, including shortened body length, microcephaly (small head) and microphthalmia (small eyes) [<xref ref-type="bibr" rid="B127">127</xref>]. The <italic>Xenopus</italic> model mostly constitutes a powerful tool with which to investigate the regulation of the FA pathway <italic>in vitro</italic> through cell-free assay systems using replicating egg extracts [<xref ref-type="bibr" rid="B124">124</xref>]. Such assays could also be utilized for screening drugs that modulate the FA pathway.</p></sec><sec><title>Disease targets and ligands</title><p>The FA pathway is required for cellular resistance to DNA crosslinking agents, including widely used anti-cancer drugs such as cisplatin, MMC and melphalan. As such, inhibition of the FA pathway will lead to sensitization of tumor cells to these drugs. Therefore, the FA pathway is an attractive target for developing small molecule inhibitors that may be clinically useful as chemosensitizers in the treatment of cancer. As described above, the FA pathway involves formation of a multi-subunit protein complex harboring E3 ligase activity, several enzymes (ubiquitin ligase and conjugating enzyme, deubiquitinating enzyme, kinase, ATPase/DNA translocase and ATPase/helicase) and many protein&#x02013;protein or protein&#x02013;DNA interactions. All of these components are potential targets for small molecule inhibitors of the FA pathway.</p><p>Drug development targeting the FA pathway is still in the early stages, and therefore not much information is available. A high-throughput cell-based screening assay for small molecule inhibitors of the FA pathway has, however, been developed by Alan D'Andrea (Dana-Farber Cancer Institute), Toshiyasu Taniguchi (Fred Hutchinson Cancer Research Center) and their colleagues [<xref ref-type="bibr" rid="B128">128</xref>]. In this screen, inhibition of DNA damage-induced FANCD2 nuclear foci formation was utilized as a readout. Continued screening is ongoing and a partial result focusing on one inhibitor, curcumin (diferuloylmethane), has been published [<xref ref-type="bibr" rid="B128">128</xref>]. Curcumin is a low-molecular-weight polyphenol derived from the rhizome <italic>Curcuma longa</italic> and is the principal ingredient in the spice turmeric [<xref ref-type="bibr" rid="B129">129</xref>]. Curcumin inhibits FANCD2 monoubiquitylation and nuclear foci formation, although its exact target in the FA pathway has not been identified [<xref ref-type="bibr" rid="B128">128</xref>]. However, curcumin sensitizes an ovarian cancer cell line to cisplatin in an FA pathway-dependent manner, suggesting that curcumin sensitization of cisplatin mostly occurs through FA pathway inhibition [<xref ref-type="bibr" rid="B128">128</xref>]. In order to establish curcumin as a useful cisplatin chemosensitizer, a detailed isobologram analysis of combinations of curcumin with cisplatin, <italic>in vivo</italic> studies using mouse models, and identification of the target of curcumin in the FA pathway are required.</p></sec><sec><title>New frontiers in drug discovery</title><p>Elucidating the mechanism of action of the candidate inhibitors identified in the above-mentioned screen [<xref ref-type="bibr" rid="B128">128</xref>] will be crucial for development of specific and effective inhibitors of the FA pathway, and for further understanding the regulation of the FA pathway. Precise analyses of the effects of each drug on individual steps in the FA pathway will be required to identify their specific targets. These analyses will include <italic>in vitro</italic> ATR kinase assay, <italic>in vitro</italic> UBE2T and FANCL autoubiquitylation assays, assessment of FA core complex formation and evaluation of nuclear foci formation of DNA repair proteins including BRCA1. A better understanding of the regulatory mechanisms, as well as the identification of new partners of the FA pathway, is also crucial for the identification and development of FA pathway inhibitors. Although multiple groups have been working on structural analysis of FA proteins [<xref ref-type="bibr" rid="B130">130</xref>,<xref ref-type="bibr" rid="B131">131</xref>], so far few FA protein crystal structures (BRCA2/FANCD1 [<xref ref-type="bibr" rid="B130">130</xref>] and FANCF [<xref ref-type="bibr" rid="B131">131</xref>]) have been reported, but such studies could provide useful information for drug design as well as for elucidation of the targets of the candidate inhibitors.</p></sec><sec><title>Abbreviations</title><p>FA: Fanconi anemia; MMC: mitomycin C; TLS: translesion synthesis; HR: homologous recombination; PCNA: proliferating cell nuclear antigen; PHD: plant homeodomain.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Publication history</title><p>Republished from Current BioData's Targeted Proteins database (TPdb; <ext-link ext-link-type="uri" xlink:href="http://www.targetedproteinsdb.com"/>).</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Anindya Dutta, Alan D. D'Andrea, Nazneen Rahman, Johan de Winter, Hans Joenje and Bing Xia for sharing data prior to publication. We thank Wataru Sakai and Emily Villegas for critical reading of the manuscript. CJ is supported by Fondation Betancourt. TT is a Searle Scholar and a V Scholar. We apologize that we cannot cite some of the important literature on FA due to the limitation of space.</p><p>This article has been published as part of <italic>BMC Biochemistry</italic> Volume 8 Supplement 1, 2007: Ubiquitin-Proteasome System in Disease Part 1. The full contents of the supplement are available online at <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2091/8?issue=S1"/>.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name></person-group><article-title>The emerging genetic and molecular basis of Fanconi anaemia</article-title><source>Nat Rev Genet</source><year>2001</year><volume>2</volume><fpage>446</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">11389461</pub-id><pub-id pub-id-type="doi">10.1038/35076590</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>Levitus</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Medhurst</surname><given-names>AL</given-names></name><name><surname>Zwaan</surname><given-names>M</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Rooimans</surname><given-names>MA</given-names></name><name><surname>Bier</surname><given-names>P</given-names></name><name><surname>Hoatlin</surname><given-names>M</given-names></name><name><surname>Pals</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>X-linked inheritance of Fanconi anemia complementation group B</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>1219</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">15502827</pub-id><pub-id pub-id-type="doi">10.1038/ng1458</pub-id></citation></ref><ref id="B3"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>BP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Nathan DG, Orkin SH, Ginsburg D, Look AT, Oski FA</surname></name></person-group><article-title>Inherited bone marrow failure syndromes</article-title><source>Nathan and Oski's Hematology of Infancy and Childhood</source><year>2003</year><volume>1</volume><edition>6</edition><publisher-name>Philadelphia: PA Saunders</publisher-name><fpage>280</fpage><lpage>365</lpage></citation></ref><ref id="B4"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Auerbach</surname><given-names>AD</given-names></name><name><surname>Buchwald</surname><given-names>M</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Scriver CR, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Vogelstein B</surname></name></person-group><article-title>Fanconi Anemia</article-title><source>The Metabolic and Molecular Bases of Inherited Disease</source><year>2001</year><volume>1</volume><edition>8th edn</edition><publisher-name>New York: McGraw-Hill</publisher-name><fpage>753</fpage><lpage>768</lpage></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name></person-group><article-title>The Fanconi anaemia/BRCA pathway</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12509764</pub-id><pub-id pub-id-type="doi">10.1038/nrc970</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Molecular pathogenesis of Fanconi anemia: recent progress</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>4223</fpage><lpage>4233</lpage><pub-id pub-id-type="pmid">16493006</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-10-4240</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>RD</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>The Fanconi Anemia/BRCA pathway: new faces in the crowd</article-title><source>Genes Dev</source><year>2005</year><volume>19</volume><fpage>2925</fpage><lpage>2940</lpage><pub-id pub-id-type="pmid">16357213</pub-id><pub-id pub-id-type="doi">10.1101/gad.1370505</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirchandani</surname><given-names>KD</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair</article-title><source>Exp Cell Res</source><year>2006</year><volume>312</volume><fpage>2647</fpage><lpage>2653</lpage><pub-id pub-id-type="pmid">16859679</pub-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2006.06.014</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurtan</surname><given-names>AM</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Dedicated to the core: understanding the Fanconi anemia complex</article-title><source>DNA Repair (Amst)</source><year>2006</year><volume>5</volume><fpage>1119</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">16784902</pub-id><pub-id pub-id-type="doi">10.1016/j.dnarep.2006.05.009</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>CG</given-names></name></person-group><article-title>Fanconi anaemia genes and susceptibility to cancer</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>5875</fpage><lpage>5884</lpage><pub-id pub-id-type="pmid">16998502</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209878</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><article-title>Tracing the network connecting BRCA and Fanconi anaemia proteins</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>266</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">15057286</pub-id><pub-id pub-id-type="doi">10.1038/nrc1321</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bagby</surname><given-names>GC</given-names></name><name><surname>Alter</surname><given-names>BP</given-names></name></person-group><article-title>Fanconi anemia</article-title><source>Semin Hematol</source><year>2006</year><volume>43</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">16822457</pub-id><pub-id pub-id-type="doi">10.1053/j.seminhematol.2006.04.005</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niedernhofer</surname><given-names>LJ</given-names></name><name><surname>Lalai</surname><given-names>AS</given-names></name><name><surname>Hoeijmakers</surname><given-names>JH</given-names></name></person-group><article-title>Fanconi Anemia (Cross)linked to DNA Repair</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">16377561</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2005.12.009</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyakhovich</surname><given-names>A</given-names></name><name><surname>Surralles</surname><given-names>J</given-names></name></person-group><article-title>Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer</article-title><source>Cancer Lett</source><year>2006</year><volume>232</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">16246487</pub-id><pub-id pub-id-type="doi">10.1016/j.canlet.2005.07.038</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>N</given-names></name><name><surname>Kupfer</surname><given-names>GM</given-names></name></person-group><article-title>Molecular pathogenesis of Fanconi anemia</article-title><source>Int J Hematol</source><year>2005</year><volume>82</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">16207587</pub-id><pub-id pub-id-type="doi">10.1532/IJH97.05108</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tischkowitz</surname><given-names>M</given-names></name><name><surname>Dokal</surname><given-names>I</given-names></name></person-group><article-title>Fanconi anaemia and leukaemia - clinical and molecular aspects</article-title><source>Br J Haematol</source><year>2004</year><volume>126</volume><fpage>176</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">15238138</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2141.2004.05023.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutler</surname><given-names>DI</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Satagopan</surname><given-names>J</given-names></name><name><surname>Batish</surname><given-names>SD</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name><name><surname>Giampietro</surname><given-names>PF</given-names></name><name><surname>Hanenberg</surname><given-names>H</given-names></name><name><surname>Auerbach</surname><given-names>AD</given-names></name></person-group><article-title>A 20-year perspective on the International Fanconi Anemia Registry (IFAR)</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>1249</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">12393516</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-07-2170</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>PS</given-names></name><name><surname>Greene</surname><given-names>MH</given-names></name><name><surname>Alter</surname><given-names>BP</given-names></name></person-group><article-title>Cancer incidence in persons with Fanconi anemia</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>822</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">12393424</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-05-1498</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>BP</given-names></name></person-group><article-title>Cancer in Fanconi anemia, 1927-2001</article-title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>425</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">12518367</pub-id><pub-id pub-id-type="doi">10.1002/cncr.11046</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>JE</given-names></name><name><surname>Tolar</surname><given-names>J</given-names></name><name><surname>Levran</surname><given-names>O</given-names></name><name><surname>Scholl</surname><given-names>T</given-names></name><name><surname>Deffenbaugh</surname><given-names>A</given-names></name><name><surname>Satagopan</surname><given-names>J</given-names></name><name><surname>Ben-Porat</surname><given-names>L</given-names></name><name><surname>Mah</surname><given-names>K</given-names></name><name><surname>Batish</surname><given-names>SD</given-names></name><name><surname>Kutler</surname><given-names>DI</given-names></name><etal></etal></person-group><article-title>Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>3226</fpage><lpage>3229</lpage><pub-id pub-id-type="pmid">15070707</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-09-3138</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Levran</surname><given-names>O</given-names></name><name><surname>Mullaney</surname><given-names>B</given-names></name><name><surname>Mah</surname><given-names>K</given-names></name><name><surname>Nafa</surname><given-names>K</given-names></name><name><surname>Batish</surname><given-names>SD</given-names></name><name><surname>Diotti</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Deffenbaugh</surname><given-names>A</given-names></name><name><surname>Scholl</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia</article-title><source>J Natl Cancer Inst</source><year>2003</year><volume>95</volume><fpage>1548</fpage><lpage>1551</lpage><pub-id pub-id-type="pmid">14559878</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>B</given-names></name><name><surname>Shimamura</surname><given-names>A</given-names></name><name><surname>Moreau</surname><given-names>L</given-names></name><name><surname>Baldinger</surname><given-names>S</given-names></name><name><surname>Hag-Alshiekh</surname><given-names>M</given-names></name><name><surname>Bostrom</surname><given-names>B</given-names></name><name><surname>Sencer</surname><given-names>S</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>2554</fpage><lpage>2559</lpage><pub-id pub-id-type="pmid">14670928</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-06-1970</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Dorsman</surname><given-names>JC</given-names></name><name><surname>Ameziane</surname><given-names>N</given-names></name><name><surname>de Vries</surname><given-names>Y</given-names></name><name><surname>Rooimans</surname><given-names>MA</given-names></name><name><surname>Sheng</surname><given-names>Q</given-names></name><name><surname>Pals</surname><given-names>G</given-names></name><name><surname>Errami</surname><given-names>A</given-names></name><name><surname>Gluckman</surname><given-names>E</given-names></name><name><surname>Llera</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Fanconi anemia is associated with a defect in the BRCA2 partner PALB2</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">17200672</pub-id><pub-id pub-id-type="doi">10.1038/ng1942</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>S</given-names></name><name><surname>Schindler</surname><given-names>D</given-names></name><name><surname>Hanenberg</surname><given-names>H</given-names></name><name><surname>Barker</surname><given-names>K</given-names></name><name><surname>Hanks</surname><given-names>S</given-names></name><name><surname>Kalb</surname><given-names>R</given-names></name><name><surname>Neveling</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Freund</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Biallelic mutations in <italic>PALB2</italic>, which encodes a BRCA2 interacting protein, cause Fanconi anemia subtype FA-N and predispose to childhood cancer</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>162</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">17200671</pub-id><pub-id pub-id-type="doi">10.1038/ng1947</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>MS</given-names></name><name><surname>Tonomura</surname><given-names>A</given-names></name></person-group><article-title>A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents</article-title><source>Cancer Research</source><year>1973</year><volume>33</volume><fpage>1829</fpage><lpage>1836</lpage><pub-id pub-id-type="pmid">4352739</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auerbach</surname><given-names>AD</given-names></name></person-group><article-title>Fanconi anemia diagnosis and the diepoxybutane (DEB) test</article-title><source>Experimental Hematology</source><year>1993</year><volume>21</volume><fpage>731</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">8500573</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>Medhurst</surname><given-names>AL</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Singh</surname><given-names>TR</given-names></name><name><surname>Bier</surname><given-names>P</given-names></name><name><surname>Steltenpool</surname><given-names>J</given-names></name><name><surname>Stone</surname><given-names>S</given-names></name><name><surname>Dokal</surname><given-names>I</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><etal></etal></person-group><article-title>A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>958</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">16116422</pub-id><pub-id pub-id-type="doi">10.1038/ng1626</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levitus</surname><given-names>M</given-names></name><name><surname>Rooimans</surname><given-names>MA</given-names></name><name><surname>Steltenpool</surname><given-names>J</given-names></name><name><surname>Cool</surname><given-names>NF</given-names></name><name><surname>Oostra</surname><given-names>AB</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Hoatlin</surname><given-names>ME</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name><name><surname>De Winter</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>2498</fpage><lpage>2503</lpage><pub-id pub-id-type="pmid">14630800</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-08-2915</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levitus</surname><given-names>M</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>Godthelp</surname><given-names>BC</given-names></name><name><surname>Vries</surname><given-names>Y</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Wiegant</surname><given-names>WW</given-names></name><name><surname>Elghalbzouri-Maghrani</surname><given-names>E</given-names></name><name><surname>Steltenpool</surname><given-names>J</given-names></name><name><surname>Rooimans</surname><given-names>MA</given-names></name><name><surname>Pals</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>934</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">16116423</pub-id><pub-id pub-id-type="doi">10.1038/ng1625</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levran</surname><given-names>O</given-names></name><name><surname>Attwooll</surname><given-names>C</given-names></name><name><surname>Henry</surname><given-names>RT</given-names></name><name><surname>Milton</surname><given-names>KL</given-names></name><name><surname>Neveling</surname><given-names>K</given-names></name><name><surname>Rio</surname><given-names>P</given-names></name><name><surname>Batish</surname><given-names>SD</given-names></name><name><surname>Kalb</surname><given-names>R</given-names></name><name><surname>Velleuer</surname><given-names>E</given-names></name><name><surname>Barral</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>931</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">16116424</pub-id><pub-id pub-id-type="doi">10.1038/ng1624</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>NG</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>B</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>De Die-Smulders</surname><given-names>C</given-names></name><name><surname>Persky</surname><given-names>N</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Pals</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Biallelic inactivation of BRCA2 in Fanconi anemia</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>606</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">12065746</pub-id><pub-id pub-id-type="doi">10.1126/science.1073834</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Sheng</surname><given-names>Q</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Christ</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><article-title>Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2</article-title><source>Mol Cell</source><year>2006</year><volume>22</volume><fpage>719</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">16793542</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2006.05.022</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Litman</surname><given-names>R</given-names></name><name><surname>Peng</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Powell</surname><given-names>S</given-names></name><name><surname>Andreassen</surname><given-names>PR</given-names></name><name><surname>Cantor</surname><given-names>SB</given-names></name></person-group><article-title>BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ</article-title><source>Cancer Cell</source><year>2005</year><volume>8</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">16153896</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2005.08.004</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Higuera</surname><given-names>I</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Meyn</surname><given-names>MS</given-names></name><name><surname>Timmers</surname><given-names>C</given-names></name><name><surname>Hejna</surname><given-names>J</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway</article-title><source>Mol Cell</source><year>2001</year><volume>7</volume><fpage>249</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">11239454</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00173-3</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Andreassen</surname><given-names>PR</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>5850</fpage><lpage>5862</lpage><pub-id pub-id-type="pmid">15199141</pub-id><pub-id pub-id-type="doi">10.1128/MCB.24.13.5850-5862.2004</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vandenberg</surname><given-names>CJ</given-names></name><name><surname>Gergely</surname><given-names>F</given-names></name><name><surname>Ong</surname><given-names>CY</given-names></name><name><surname>Pace</surname><given-names>P</given-names></name><name><surname>Mallery</surname><given-names>DL</given-names></name><name><surname>Hiom</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name></person-group><article-title>BRCA1-independent ubiquitination of FANCD2</article-title><source>Mol Cell</source><year>2003</year><volume>12</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">12887909</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00281-8</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>Sechi</surname><given-names>S</given-names></name><name><surname>Wallisch</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>MK</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Hoatlin</surname><given-names>ME</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><fpage>3417</fpage><lpage>3426</lpage><pub-id pub-id-type="pmid">12724401</pub-id><pub-id pub-id-type="doi">10.1128/MCB.23.10.3417-3426.2003</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>de Winter</surname><given-names>JP</given-names></name><name><surname>Medhurst</surname><given-names>AL</given-names></name><name><surname>Wallisch</surname><given-names>M</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>van de Vrugt</surname><given-names>HJ</given-names></name><name><surname>Oostra</surname><given-names>AB</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Bishop</surname><given-names>CE</given-names></name><etal></etal></person-group><article-title>A novel ubiquitin ligase is deficient in Fanconi anemia</article-title><source>Nat Genet</source><year>2003</year><volume>35</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">12973351</pub-id><pub-id pub-id-type="doi">10.1038/ng1241</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aravind</surname><given-names>L</given-names></name><name><surname>Iyer</surname><given-names>LM</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name></person-group><article-title>Scores of RINGS but no PHDs in ubiquitin signaling</article-title><source>Cell Cycle</source><year>2003</year><volume>2</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">12695663</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheel</surname><given-names>H</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name></person-group><article-title>No evidence for PHD fingers as ubiquitin ligases</article-title><source>Trends Cell Biol</source><year>2003</year><volume>13</volume><fpage>285</fpage><lpage>287</lpage><comment>author reply 287-288</comment><pub-id pub-id-type="pmid">12791292</pub-id><pub-id pub-id-type="doi">10.1016/S0962-8924(03)00102-8</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bienz</surname><given-names>M</given-names></name></person-group><article-title>The PHD finger, a nuclear protein-interaction domain</article-title><source>Trends Biochem Sci</source><year>2006</year><volume>31</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16297627</pub-id><pub-id pub-id-type="doi">10.1016/j.tibs.2005.11.001</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Machida</surname><given-names>YJ</given-names></name><name><surname>Machida</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gurtan</surname><given-names>AM</given-names></name><name><surname>Kupfer</surname><given-names>GM</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Dutta</surname><given-names>A</given-names></name></person-group><article-title>UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation</article-title><source>Mol Cell</source><year>2006</year><volume>23</volume><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">16916645</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2006.06.024</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>WH</given-names></name><name><surname>Margossian</surname><given-names>S</given-names></name><name><surname>Horwitz</surname><given-names>AA</given-names></name><name><surname>Simons</surname><given-names>AM</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Parvin</surname><given-names>JD</given-names></name></person-group><article-title>Direct DNA binding activity of the Fanconi anemia D2 protein</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>23593</fpage><lpage>23598</lpage><pub-id pub-id-type="pmid">15849361</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M503730200</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montes de Oca</surname><given-names>R</given-names></name><name><surname>Andreassen</surname><given-names>PR</given-names></name><name><surname>Margossian</surname><given-names>SP</given-names></name><name><surname>Gregory</surname><given-names>RC</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Houghtaling</surname><given-names>S</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>1003</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">15454491</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-11-3997</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Garcia-Higuera</surname><given-names>I</given-names></name><name><surname>Andreassen</surname><given-names>PR</given-names></name><name><surname>Gregory</surname><given-names>RC</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2414</fpage><lpage>2420</lpage><pub-id pub-id-type="pmid">12239151</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-01-0278</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>PR</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><article-title>ATR couples FANCD2 monoubiquitination to the DNA-damage response</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><fpage>1958</fpage><lpage>1963</lpage><pub-id pub-id-type="pmid">15314022</pub-id><pub-id pub-id-type="doi">10.1101/gad.1196104</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Kitao</surname><given-names>H</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Nagashima</surname><given-names>N</given-names></name><name><surname>Hirano</surname><given-names>S</given-names></name><name><surname>Okawa</surname><given-names>K</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>DS</given-names></name><name><surname>McHugh</surname><given-names>PJ</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name><etal></etal></person-group><article-title>A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair</article-title><source>Mol Cell</source><year>2005</year><volume>19</volume><fpage>841</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">16168378</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2005.08.018</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nijman</surname><given-names>SM</given-names></name><name><surname>Huang</surname><given-names>TT</given-names></name><name><surname>Dirac</surname><given-names>AM</given-names></name><name><surname>Brummelkamp</surname><given-names>TR</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><article-title>The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway</article-title><source>Mol Cell</source><year>2005</year><volume>17</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">15694335</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2005.01.008</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>TT</given-names></name><name><surname>Nijman</surname><given-names>SM</given-names></name><name><surname>Mirchandani</surname><given-names>KD</given-names></name><name><surname>Galardy</surname><given-names>PJ</given-names></name><name><surname>Cohn</surname><given-names>MA</given-names></name><name><surname>Haas</surname><given-names>W</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Regulation of monoubiquitinated PCNA by DUB autocleavage</article-title><source>Nat Cell Biol</source><year>2006</year><volume>8</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">16531995</pub-id><pub-id pub-id-type="doi">10.1038/ncb1378</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kannouche</surname><given-names>PL</given-names></name><name><surname>Wing</surname><given-names>J</given-names></name><name><surname>Lehmann</surname><given-names>AR</given-names></name></person-group><article-title>Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage</article-title><source>Mol Cell</source><year>2004</year><volume>14</volume><fpage>491</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">15149598</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(04)00259-X</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoege</surname><given-names>C</given-names></name><name><surname>Pfander</surname><given-names>B</given-names></name><name><surname>Moldovan</surname><given-names>GL</given-names></name><name><surname>Pyrowolakis</surname><given-names>G</given-names></name><name><surname>Jentsch</surname><given-names>S</given-names></name></person-group><article-title>RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO</article-title><source>Nature</source><year>2002</year><volume>419</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">12226657</pub-id><pub-id pub-id-type="doi">10.1038/nature00991</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dronkert</surname><given-names>ML</given-names></name><name><surname>Kanaar</surname><given-names>R</given-names></name></person-group><article-title>Repair of DNA interstrand cross-links</article-title><source>Mutat Res</source><year>2001</year><volume>486</volume><fpage>217</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">11516927</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niedzwiedz</surname><given-names>W</given-names></name><name><surname>Mosedale</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Ong</surname><given-names>CY</given-names></name><name><surname>Pace</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name></person-group><article-title>The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair</article-title><source>Mol Cell</source><year>2004</year><volume>15</volume><fpage>607</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">15327776</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2004.08.009</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Ranganathan</surname><given-names>V</given-names></name><name><surname>New</surname><given-names>HV</given-names></name><name><surname>Moreau</surname><given-names>LA</given-names></name><name><surname>Stotsky</surname><given-names>M</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>Weaver</surname><given-names>DT</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Interaction of FANCD2 and NBS1 in the DNA damage response</article-title><source>Nat Cell Biol</source><year>2002</year><volume>4</volume><fpage>913</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">12447395</pub-id><pub-id pub-id-type="doi">10.1038/ncb879</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pace</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>WM</given-names></name><name><surname>Mosedale</surname><given-names>G</given-names></name><name><surname>Sng</surname><given-names>C</given-names></name><name><surname>Hoatlin</surname><given-names>M</given-names></name><name><surname>de Winter</surname><given-names>J</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Gergely</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name></person-group><article-title>FANCE: the link between Fanconi anaemia complex assembly and activity</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><fpage>3414</fpage><lpage>3423</lpage><pub-id pub-id-type="pmid">12093742</pub-id><pub-id pub-id-type="doi">10.1093/emboj/cdf355</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Witt</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>PA</given-names></name><name><surname>Medhurst</surname><given-names>AL</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name></person-group><article-title>Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>2503</fpage><lpage>2510</lpage><pub-id pub-id-type="pmid">12915460</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddg266</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moynahan</surname><given-names>ME</given-names></name><name><surname>Pierce</surname><given-names>AJ</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><article-title>BRCA2 is required for homology-directed repair of chromosomal breaks</article-title><source>Mol Cell</source><year>2001</year><volume>7</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">11239455</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00174-5</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>AA</given-names></name><name><surname>Masson</surname><given-names>JY</given-names></name><name><surname>McIlwraith</surname><given-names>MJ</given-names></name><name><surname>Stasiak</surname><given-names>AZ</given-names></name><name><surname>Stasiak</surname><given-names>A</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name><name><surname>West</surname><given-names>SC</given-names></name></person-group><article-title>Role of BRCA2 in control of the RAD51 recombination and DNA repair protein</article-title><source>Mol Cell</source><year>2001</year><volume>7</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">11239456</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00175-7</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Digweed</surname><given-names>M</given-names></name><name><surname>Rothe</surname><given-names>S</given-names></name><name><surname>Demuth</surname><given-names>I</given-names></name><name><surname>Scholz</surname><given-names>R</given-names></name><name><surname>Schindler</surname><given-names>D</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>A</given-names></name><name><surname>Sperling</surname><given-names>K</given-names></name></person-group><article-title>Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia</article-title><source>Carcinogenesis</source><year>2002</year><volume>23</volume><fpage>1121</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">12117768</pub-id><pub-id pub-id-type="doi">10.1093/carcin/23.7.1121</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pichierri</surname><given-names>P</given-names></name><name><surname>Averbeck</surname><given-names>D</given-names></name><name><surname>Rosselli</surname><given-names>F</given-names></name></person-group><article-title>DNA cross-link-dependent RAD50/MRE11/NBS1 subnuclear assembly requires the Fanconi anemia C protein</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>2531</fpage><lpage>2546</lpage><pub-id pub-id-type="pmid">12354779</pub-id><pub-id pub-id-type="doi">10.1093/hmg/11.21.2531</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>JM</given-names></name><name><surname>Pierce</surname><given-names>AJ</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Pastink</surname><given-names>A</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><article-title>Genetic steps of mammalian homologous repair with distinct mutagenic consequences</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>9305</fpage><lpage>9316</lpage><pub-id pub-id-type="pmid">15485900</pub-id><pub-id pub-id-type="doi">10.1128/MCB.24.21.9305-9316.2004</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>YG</given-names></name><name><surname>Pierce</surname><given-names>AJ</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Digweed</surname><given-names>M</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><article-title>Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>1110</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">15650050</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0407796102</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Godthelp</surname><given-names>BC</given-names></name><name><surname>Wiegant</surname><given-names>WW</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>Medhurst</surname><given-names>AL</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Zdzienicka</surname><given-names>MZ</given-names></name></person-group><article-title>Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2</article-title><source>Mutat Res</source><year>2006</year><volume>594</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">16154163</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YG</given-names></name><name><surname>Herceg</surname><given-names>Z</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Demuth</surname><given-names>I</given-names></name><name><surname>Piccoli</surname><given-names>C</given-names></name><name><surname>Michelon</surname><given-names>J</given-names></name><name><surname>Hildebrand</surname><given-names>G</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name><name><surname>Digweed</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name></person-group><article-title>The Fanconi anemia group A protein modulates homologous repair of DNA double-strand breaks in mammalian cells</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>1731</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">15905196</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgi134</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Yamazoe</surname><given-names>M</given-names></name><name><surname>Seki</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Ohzeki</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>YM</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Buerstedde</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Functional relationships of FANCC to homologous recombination, translesion synthesis, and BLM</article-title><source>Embo J</source><year>2005</year><volume>24</volume><fpage>418</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">15616572</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600534</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Hirano</surname><given-names>S</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Morishima</surname><given-names>K</given-names></name><name><surname>Kitao</surname><given-names>H</given-names></name><name><surname>Namikoshi</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Buerstedde</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">15601828</pub-id><pub-id pub-id-type="doi">10.1128/MCB.25.1.34-43.2005</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Lamerdin</surname><given-names>JE</given-names></name><name><surname>Buerstedde</surname><given-names>JM</given-names></name><name><surname>Tanimoto</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>LH</given-names></name><name><surname>Takata</surname><given-names>M</given-names></name></person-group><article-title>Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><fpage>5421</fpage><lpage>5430</lpage><pub-id pub-id-type="pmid">12861027</pub-id><pub-id pub-id-type="doi">10.1128/MCB.23.15.5421-5430.2003</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bridge</surname><given-names>WL</given-names></name><name><surname>Vandenberg</surname><given-names>CJ</given-names></name><name><surname>Franklin</surname><given-names>RJ</given-names></name><name><surname>Hiom</surname><given-names>K</given-names></name></person-group><article-title>The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>953</fpage><lpage>957</lpage><pub-id pub-id-type="pmid">16116421</pub-id><pub-id pub-id-type="doi">10.1038/ng1627</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>A</given-names></name><name><surname>Zdzienicka</surname><given-names>MZ</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name></person-group><article-title>Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>14877</fpage><lpage>14883</lpage><pub-id pub-id-type="pmid">15671039</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M414669200</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosedale</surname><given-names>G</given-names></name><name><surname>Niedzwiedz</surname><given-names>W</given-names></name><name><surname>Alpi</surname><given-names>A</given-names></name><name><surname>Perrina</surname><given-names>F</given-names></name><name><surname>Pereira-Leal</surname><given-names>JB</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Langevin</surname><given-names>F</given-names></name><name><surname>Pace</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name></person-group><article-title>The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway</article-title><source>Nat Struct Mol Biol</source><year>2005</year><volume>12</volume><fpage>763</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">16116434</pub-id><pub-id pub-id-type="doi">10.1038/nsmb981</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>SB</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Kass</surname><given-names>EM</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Grossman</surname><given-names>S</given-names></name><name><surname>Wahrer</surname><given-names>DC</given-names></name><name><surname>Sgroi</surname><given-names>DC</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><etal></etal></person-group><article-title>BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function</article-title><source>Cell</source><year>2001</year><volume>105</volume><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">11301010</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00304-X</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manke</surname><given-names>IA</given-names></name><name><surname>Lowery</surname><given-names>DM</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Yaffe</surname><given-names>MB</given-names></name></person-group><article-title>BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>636</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">14576432</pub-id><pub-id pub-id-type="doi">10.1126/science.1088877</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Chini</surname><given-names>CC</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Mer</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>The BRCT domain is a phospho-protein binding domain</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>639</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">14576433</pub-id><pub-id pub-id-type="doi">10.1126/science.1088753</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Garcia-Higuera</surname><given-names>I</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Andreassen</surname><given-names>PR</given-names></name><name><surname>Gregory</surname><given-names>RC</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways</article-title><source>Cell</source><year>2002</year><volume>109</volume><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">12086603</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00747-X</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fagerlie</surname><given-names>SR</given-names></name><name><surname>Koretsky</surname><given-names>T</given-names></name><name><surname>Torok-Storb</surname><given-names>B</given-names></name><name><surname>Bagby</surname><given-names>GC</given-names></name></person-group><article-title>Impaired type I IFN-induced Jak/STAT signaling in FA-C cells and abnormal CD4+ Th cell subsets in Fancc-/- mice</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>3863</fpage><lpage>3870</lpage><pub-id pub-id-type="pmid">15356134</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sejas</surname><given-names>DP</given-names></name><name><surname>Rathbun</surname><given-names>KR</given-names></name><name><surname>Bagby</surname><given-names>GC</given-names></name><name><surname>Pang</surname><given-names>Q</given-names></name></person-group><article-title>The Fanconi anemia proteins functionally interact with the protein kinase regulated by RNA (PKR)</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>43910</fpage><lpage>43919</lpage><pub-id pub-id-type="pmid">15299030</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M403884200</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saadatzadeh</surname><given-names>MR</given-names></name><name><surname>Bijangi-Vishehsaraei</surname><given-names>K</given-names></name><name><surname>Hong</surname><given-names>P</given-names></name><name><surname>Bergmann</surname><given-names>H</given-names></name><name><surname>Haneline</surname><given-names>LS</given-names></name></person-group><article-title>Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>16805</fpage><lpage>16812</lpage><pub-id pub-id-type="pmid">14764578</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M313721200</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Q</given-names></name><name><surname>Christianson</surname><given-names>TA</given-names></name><name><surname>Keeble</surname><given-names>W</given-names></name><name><surname>Koretsky</surname><given-names>T</given-names></name><name><surname>Bagby</surname><given-names>GC</given-names></name></person-group><article-title>The anti-apoptotic function of Hsp70 in the PKR-mediated death signaling pathway requires the Fanconi anemia protein, FANCC</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>49638</fpage><lpage>49643</lpage><pub-id pub-id-type="pmid">12397061</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M209386200</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Q</given-names></name><name><surname>Fagerlie</surname><given-names>S</given-names></name><name><surname>Christianson</surname><given-names>TA</given-names></name><name><surname>Keeble</surname><given-names>W</given-names></name><name><surname>Faulkner</surname><given-names>G</given-names></name><name><surname>Diaz</surname><given-names>J</given-names></name><name><surname>Rathbun</surname><given-names>RK</given-names></name><name><surname>Bagby</surname><given-names>GC</given-names></name></person-group><article-title>The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors</article-title><source>Mol Cell Biol</source><year>2000</year><volume>20</volume><fpage>4724</fpage><lpage>4735</lpage><pub-id pub-id-type="pmid">10848598</pub-id><pub-id pub-id-type="doi">10.1128/MCB.20.13.4724-4735.2000</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brodeur</surname><given-names>I</given-names></name><name><surname>Goulet</surname><given-names>I</given-names></name><name><surname>Tremblay</surname><given-names>CS</given-names></name><name><surname>Charbonneau</surname><given-names>C</given-names></name><name><surname>Delisle</surname><given-names>MC</given-names></name><name><surname>Godin</surname><given-names>C</given-names></name><name><surname>Huard</surname><given-names>C</given-names></name><name><surname>Khandjian</surname><given-names>EW</given-names></name><name><surname>Buchwald</surname><given-names>M</given-names></name><name><surname>Levesque</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Regulation of the Fanconi anemia group C protein through proteolytic modification</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>4713</fpage><lpage>4720</lpage><pub-id pub-id-type="pmid">14625294</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M301291200</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Tischkowitz</surname><given-names>M</given-names></name><name><surname>Ameziane</surname><given-names>N</given-names></name><name><surname>Hodgson</surname><given-names>SV</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>568</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">12692539</pub-id><pub-id pub-id-type="doi">10.1038/nm852</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway</article-title><source>Cancer Biol Ther</source><year>2006</year><volume>5</volume><fpage>256</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">16418574</pub-id><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0299</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhillon</surname><given-names>VS</given-names></name><name><surname>Shahid</surname><given-names>M</given-names></name><name><surname>Husain</surname><given-names>SA</given-names></name></person-group><article-title>CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin</article-title><source>Mol Cancer</source><year>2004</year><volume>3</volume><fpage>33</fpage><pub-id pub-id-type="pmid">15574200</pub-id><pub-id pub-id-type="doi">10.1186/1476-4598-3-33</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name></person-group><article-title>FANCF methylation contributes to chemoselectivity in ovarian cancer</article-title><source>Cancer Cell</source><year>2003</year><volume>3</volume><fpage>417</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">12781358</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00111-9</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marsit</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Nelson</surname><given-names>HH</given-names></name><name><surname>Posner</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Kelsey</surname><given-names>KT</given-names></name></person-group><article-title>Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>1000</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">14647419</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207256</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>G</given-names></name><name><surname>Arias-Pulido</surname><given-names>H</given-names></name><name><surname>Nandula</surname><given-names>SV</given-names></name><name><surname>Basso</surname><given-names>K</given-names></name><name><surname>Sugirtharaj</surname><given-names>DD</given-names></name><name><surname>Vargas</surname><given-names>H</given-names></name><name><surname>Mansukhani</surname><given-names>M</given-names></name><name><surname>Villella</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>L</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>2994</fpage><lpage>2997</lpage><pub-id pub-id-type="pmid">15126331</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0245</pub-id></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koul</surname><given-names>S</given-names></name><name><surname>McKiernan</surname><given-names>JM</given-names></name><name><surname>Narayan</surname><given-names>G</given-names></name><name><surname>Houldsworth</surname><given-names>J</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Dobrzynski</surname><given-names>DL</given-names></name><name><surname>Assaad</surname><given-names>AM</given-names></name><name><surname>Mansukhani</surname><given-names>M</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Bosl</surname><given-names>GJ</given-names></name><etal></etal></person-group><article-title>Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors</article-title><source>Mol Cancer</source><year>2004</year><volume>3</volume><fpage>16</fpage><pub-id pub-id-type="pmid">15149548</pub-id><pub-id pub-id-type="doi">10.1186/1476-4598-3-16</pub-id></citation></ref><ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tischkowitz</surname><given-names>M</given-names></name><name><surname>Ameziane</surname><given-names>N</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>De Winter</surname><given-names>JP</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>D'Andrea</surname><given-names>A</given-names></name><name><surname>Hodgson</surname><given-names>SV</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name></person-group><article-title>Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia</article-title><source>Br J Haematol</source><year>2003</year><volume>123</volume><fpage>469</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">14617007</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2141.2003.04640.x</pub-id></citation></ref><ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Der Heijden</surname><given-names>MS</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><article-title>Fanconi anemia gene mutations in young-onset pancreatic cancer</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>2585</fpage><lpage>2588</lpage><pub-id pub-id-type="pmid">12750283</pub-id></citation></ref><ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Der Heijden</surname><given-names>MS</given-names></name><name><surname>Brody</surname><given-names>JR</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><article-title>Functional screen of the Fanconi anemia pathway in cancer cells by fancd2 immunoblot</article-title><source>Cancer Biol Ther</source><year>2004</year><volume>3</volume><fpage>534</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">15107617</pub-id></citation></ref><ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>MS</given-names></name><name><surname>Brody</surname><given-names>JR</given-names></name><name><surname>Gallmeier</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>SC</given-names></name><name><surname>Dezentje</surname><given-names>DA</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><article-title>Functional defects in the Fanconi anemia pathway in pancreatic cancer cells</article-title><source>Am J Pathol</source><year>2004</year><volume>165</volume><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">15277238</pub-id></citation></ref><ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Condie</surname><given-names>A</given-names></name><name><surname>Powles</surname><given-names>RL</given-names></name><name><surname>Hudson</surname><given-names>CD</given-names></name><name><surname>Shepherd</surname><given-names>V</given-names></name><name><surname>Bevan</surname><given-names>S</given-names></name><name><surname>Yuille</surname><given-names>MR</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name></person-group><article-title>Analysis of the Fanconi anaemia complementation group A gene in acute myeloid leukaemia</article-title><source>Leuk Lymphoma</source><year>2002</year><volume>43</volume><fpage>1849</fpage><lpage>1853</lpage><pub-id pub-id-type="pmid">12685843</pub-id><pub-id pub-id-type="doi">10.1080/1042819021000009274</pub-id></citation></ref><ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tischkowitz</surname><given-names>MD</given-names></name><name><surname>Morgan</surname><given-names>NV</given-names></name><name><surname>Grimwade</surname><given-names>D</given-names></name><name><surname>Eddy</surname><given-names>C</given-names></name><name><surname>Ball</surname><given-names>S</given-names></name><name><surname>Vorechovsky</surname><given-names>I</given-names></name><name><surname>Langabeer</surname><given-names>S</given-names></name><name><surname>Stoger</surname><given-names>R</given-names></name><name><surname>Hodgson</surname><given-names>SV</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name></person-group><article-title>Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>420</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">14749703</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2403280</pub-id></citation></ref><ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lensch</surname><given-names>MW</given-names></name><name><surname>Tischkowitz</surname><given-names>M</given-names></name><name><surname>Christianson</surname><given-names>TA</given-names></name><name><surname>Reifsteck</surname><given-names>CA</given-names></name><name><surname>Speckhart</surname><given-names>SA</given-names></name><name><surname>Jakobs</surname><given-names>PM</given-names></name><name><surname>O'Dwyer</surname><given-names>ME</given-names></name><name><surname>Olson</surname><given-names>SB</given-names></name><name><surname>Le Beau</surname><given-names>MM</given-names></name><name><surname>Hodgson</surname><given-names>SV</given-names></name><etal></etal></person-group><article-title>Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">12637330</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-09-2781</pub-id></citation></ref><ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>Hallmarks of &#x02018;BRCAness&#x02019; in sporadic cancers</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>814</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">15510162</pub-id><pub-id pub-id-type="doi">10.1038/nrc1457</pub-id></citation></ref><ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Rabe</surname><given-names>K</given-names></name><name><surname>Boardman</surname><given-names>L</given-names></name><name><surname>McWilliams</surname><given-names>R</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name></person-group><article-title>Germ line Fanconi anemia complementation group C mutations and pancreatic cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>383</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">15695377</pub-id></citation></ref><ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Renwick</surname><given-names>A</given-names></name><name><surname>Elliott</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name><name><surname>Barfoot</surname><given-names>R</given-names></name><name><surname>Chagtai</surname><given-names>T</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Spanova</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>1239</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">17033622</pub-id><pub-id pub-id-type="doi">10.1038/ng1902</pub-id></citation></ref><ref id="B98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Van der Sluis</surname><given-names>PC</given-names></name><name><surname>Boulware</surname><given-names>D</given-names></name><name><surname>Hazlehurst</surname><given-names>LA</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name></person-group><article-title>The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>698</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">15802532</pub-id><pub-id pub-id-type="doi">10.1182/blood-2004-11-4286</pub-id></citation></ref><ref id="B99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>MS</given-names></name><name><surname>Brody</surname><given-names>JR</given-names></name><name><surname>Dezentje</surname><given-names>DA</given-names></name><name><surname>Gallmeier</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>SC</given-names></name><name><surname>Swartz</surname><given-names>MJ</given-names></name><name><surname>DeMarzo</surname><given-names>AM</given-names></name><name><surname>Offerhaus</surname><given-names>GJ</given-names></name><name><surname>Isacoff</surname><given-names>WH</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><etal></etal></person-group><article-title>In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>7508</fpage><lpage>7515</lpage><pub-id pub-id-type="pmid">16243825</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1048</pub-id></citation></ref><ref id="B100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>de Winter</surname><given-names>JP</given-names></name><name><surname>Mastenbroek</surname><given-names>DC</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name><name><surname>Gerritsen</surname><given-names>WR</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Kruyt</surname><given-names>FA</given-names></name></person-group><article-title>Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA</article-title><source>Cancer Gene Ther</source><year>2004</year><volume>11</volume><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">15192709</pub-id><pub-id pub-id-type="doi">10.1038/sj.cgt.7700734</pub-id></citation></ref><ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>NC</given-names></name><name><surname>van De Vrugt</surname><given-names>HJ</given-names></name><name><surname>van Der Valk</surname><given-names>MA</given-names></name><name><surname>Oostra</surname><given-names>AB</given-names></name><name><surname>Krimpenfort</surname><given-names>P</given-names></name><name><surname>de Vries</surname><given-names>Y</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Berns</surname><given-names>A</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name></person-group><article-title>Mice with a targeted disruption of the Fanconi anemia homolog fanca</article-title><source>Hum Mol Genet</source><year>2000</year><volume>9</volume><fpage>1805</fpage><lpage>1811</lpage><pub-id pub-id-type="pmid">10915769</pub-id><pub-id pub-id-type="doi">10.1093/hmg/9.12.1805</pub-id></citation></ref><ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>JC</given-names></name><name><surname>Alon</surname><given-names>N</given-names></name><name><surname>McKerlie</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>JR</given-names></name><name><surname>Meyn</surname><given-names>MS</given-names></name><name><surname>Buchwald</surname><given-names>M</given-names></name></person-group><article-title>Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>2063</fpage><lpage>2076</lpage><pub-id pub-id-type="pmid">12913077</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddg219</pub-id></citation></ref><ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Tomkins</surname><given-names>DJ</given-names></name><name><surname>Auerbach</surname><given-names>W</given-names></name><name><surname>McKerlie</surname><given-names>C</given-names></name><name><surname>Youssoufian</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Gan</surname><given-names>O</given-names></name><name><surname>Carreau</surname><given-names>M</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Groves</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia</article-title><source>Nature Genetics</source><year>1996</year><volume>12</volume><fpage>448</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">8630504</pub-id><pub-id pub-id-type="doi">10.1038/ng0496-448</pub-id></citation></ref><ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitney</surname><given-names>MA</given-names></name><name><surname>Royle</surname><given-names>G</given-names></name><name><surname>Low</surname><given-names>MJ</given-names></name><name><surname>Kelly</surname><given-names>MA</given-names></name><name><surname>Axthelm</surname><given-names>MK</given-names></name><name><surname>Reifsteck</surname><given-names>C</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Braun</surname><given-names>RE</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Rathbun</surname><given-names>RK</given-names></name><etal></etal></person-group><article-title>Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene</article-title><source>Blood</source><year>1996</year><volume>88</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">8704201</pub-id></citation></ref><ref id="B105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koomen</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>NC</given-names></name><name><surname>van de Vrugt</surname><given-names>HJ</given-names></name><name><surname>Godthelp</surname><given-names>BC</given-names></name><name><surname>van der Valk</surname><given-names>MA</given-names></name><name><surname>Oostra</surname><given-names>AB</given-names></name><name><surname>Zdzienicka</surname><given-names>MZ</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name></person-group><article-title>Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">11823446</pub-id><pub-id pub-id-type="doi">10.1093/hmg/11.3.273</pub-id></citation></ref><ref id="B106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>De Oca</surname><given-names>RM</given-names></name><name><surname>Hays</surname><given-names>T</given-names></name><name><surname>Moreau</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Seed</surname><given-names>B</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group><article-title>Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>3435</fpage><lpage>3440</lpage><pub-id pub-id-type="pmid">11719385</pub-id><pub-id pub-id-type="doi">10.1182/blood.V98.12.3435</pub-id></citation></ref><ref id="B107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houghtaling</surname><given-names>S</given-names></name><name><surname>Timmers</surname><given-names>C</given-names></name><name><surname>Noll</surname><given-names>M</given-names></name><name><surname>Finegold</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>SN</given-names></name><name><surname>Meyn</surname><given-names>MS</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name></person-group><article-title>Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice</article-title><source>Genes Dev</source><year>2003</year><volume>17</volume><fpage>2021</fpage><lpage>2035</lpage><pub-id pub-id-type="pmid">12893777</pub-id><pub-id pub-id-type="doi">10.1101/gad.1103403</pub-id></citation></ref><ref id="B108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noll</surname><given-names>M</given-names></name><name><surname>Battaile</surname><given-names>KP</given-names></name><name><surname>Bateman</surname><given-names>R</given-names></name><name><surname>Lax</surname><given-names>TP</given-names></name><name><surname>Rathbun</surname><given-names>K</given-names></name><name><surname>Reifsteck</surname><given-names>C</given-names></name><name><surname>Bagby</surname><given-names>G</given-names></name><name><surname>Finegold</surname><given-names>M</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name></person-group><article-title>Fanconi anemia group A and C double-mutant mice. Functional evidence for a multi-protein Fanconi anemia complex</article-title><source>Exp Hematol</source><year>2002</year><volume>30</volume><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">12135664</pub-id><pub-id pub-id-type="doi">10.1016/S0301-472X(02)00838-X</pub-id></citation></ref><ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agoulnik</surname><given-names>AI</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Truong</surname><given-names>C</given-names></name><name><surname>Ty</surname><given-names>MT</given-names></name><name><surname>Arango</surname><given-names>N</given-names></name><name><surname>Chada</surname><given-names>KK</given-names></name><name><surname>Bishop</surname><given-names>CE</given-names></name></person-group><article-title>A novel gene, Pog, is necessary for primordial germ cell proliferation in the mouse and underlies the germ cell deficient mutation, gcd</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>3047</fpage><lpage>3053</lpage><pub-id pub-id-type="pmid">12417526</pub-id><pub-id pub-id-type="doi">10.1093/hmg/11.24.3047</pub-id></citation></ref><ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>S</given-names></name><name><surname>Meza</surname><given-names>NW</given-names></name><name><surname>Quintana-Bustamante</surname><given-names>O</given-names></name><name><surname>Casado</surname><given-names>JA</given-names></name><name><surname>Jacome</surname><given-names>A</given-names></name><name><surname>McAllister</surname><given-names>K</given-names></name><name><surname>Puerto</surname><given-names>S</given-names></name><name><surname>Surralles</surname><given-names>J</given-names></name><name><surname>Segovia</surname><given-names>JC</given-names></name><name><surname>Bueren</surname><given-names>JA</given-names></name></person-group><article-title>Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1</article-title><source>Mol Ther</source><year>2006</year><volume>14</volume><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">16859999</pub-id><pub-id pub-id-type="doi">10.1016/j.ymthe.2006.05.018</pub-id></citation></ref><ref id="B111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carreau</surname><given-names>M</given-names></name><name><surname>Gan</surname><given-names>OI</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Doedens</surname><given-names>M</given-names></name><name><surname>McKerlie</surname><given-names>C</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name><name><surname>Buchwald</surname><given-names>M</given-names></name></person-group><article-title>Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage</article-title><source>Blood</source><year>1998</year><volume>91</volume><fpage>2737</fpage><lpage>2744</lpage><pub-id pub-id-type="pmid">9531583</pub-id></citation></ref><ref id="B112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carreau</surname><given-names>M</given-names></name></person-group><article-title>Not-so-novel phenotypes in the Fanconi anemia group D2 mouse model</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>2430</fpage><pub-id pub-id-type="pmid">14998919</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-11-3946</pub-id></citation></ref><ref id="B113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moynahan</surname><given-names>ME</given-names></name></person-group><article-title>The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>8994</fpage><lpage>9007</lpage><pub-id pub-id-type="pmid">12483515</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206177</pub-id></citation></ref><ref id="B114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rio</surname><given-names>P</given-names></name><name><surname>Segovia</surname><given-names>JC</given-names></name><name><surname>Hanenberg</surname><given-names>H</given-names></name><name><surname>Casado</surname><given-names>JA</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Gottsche</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>NC</given-names></name><name><surname>Van De Vrugt</surname><given-names>HJ</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2032</fpage><lpage>2039</lpage><pub-id pub-id-type="pmid">12200363</pub-id></citation></ref><ref id="B115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gush</surname><given-names>KA</given-names></name><name><surname>Fu</surname><given-names>KL</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>CE</given-names></name></person-group><article-title>Phenotypic correction of Fanconi anemia group C knockout mice</article-title><source>Blood</source><year>2000</year><volume>95</volume><fpage>700</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">10627482</pub-id></citation></ref><ref id="B116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noll</surname><given-names>M</given-names></name><name><surname>Bateman</surname><given-names>RL</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name></person-group><article-title>Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C</article-title><source>Mol Ther</source><year>2001</year><volume>3</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11162306</pub-id><pub-id pub-id-type="doi">10.1006/mthe.2000.0226</pub-id></citation></ref><ref id="B117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galimi</surname><given-names>F</given-names></name><name><surname>Noll</surname><given-names>M</given-names></name><name><surname>Kanazawa</surname><given-names>Y</given-names></name><name><surname>Lax</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><article-title>Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2732</fpage><lpage>2736</lpage><pub-id pub-id-type="pmid">12351379</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-04-1245</pub-id></citation></ref><ref id="B118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haneline</surname><given-names>LS</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ciccone</surname><given-names>SL</given-names></name><name><surname>Hong</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Broxmeyer</surname><given-names>HE</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Srour</surname><given-names>EF</given-names></name><name><surname>Clapp</surname><given-names>DW</given-names></name></person-group><article-title>Retroviral-mediated expression of recombinant Fancc enhances the repopulating ability of Fancc-/- hematopoietic stem cells and decreases the risk of clonal evolution</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>1299</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">12393504</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-08-2404</pub-id></citation></ref><ref id="B119"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Olsen</surname><given-names>JC</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>KW</given-names></name><name><surname>Walsh</surname><given-names>CE</given-names></name></person-group><article-title>Functional correction of Fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector</article-title><source>Mol Ther</source><year>2001</year><volume>3</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">11319908</pub-id><pub-id pub-id-type="doi">10.1006/mthe.2001.0287</pub-id></citation></ref><ref id="B120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Ramezani</surname><given-names>A</given-names></name><name><surname>Hawley</surname><given-names>RG</given-names></name><name><surname>Ebell</surname><given-names>W</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name><name><surname>Arnold</surname><given-names>LW</given-names></name><name><surname>Walsh</surname><given-names>CE</given-names></name></person-group><article-title>Phenotype correction of Fanconi anemia group a hematopoietic stem cells using lentiviral vector</article-title><source>Mol Ther</source><year>2003</year><volume>8</volume><fpage>600</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">14529833</pub-id><pub-id pub-id-type="doi">10.1016/S1525-0016(03)00223-5</pub-id></citation></ref><ref id="B121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Le Beau</surname><given-names>MM</given-names></name><name><surname>Ciccone</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>FC</given-names></name><name><surname>Freie</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>P</given-names></name><name><surname>Orazi</surname><given-names>A</given-names></name><name><surname>Haneline</surname><given-names>LS</given-names></name><etal></etal></person-group><article-title>Ex vivo culture of Fancc-/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>3465</fpage><lpage>3471</lpage><pub-id pub-id-type="pmid">15644418</pub-id><pub-id pub-id-type="doi">10.1182/blood-2004-06-2483</pub-id></citation></ref><ref id="B122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carreau</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Gan</surname><given-names>OI</given-names></name><name><surname>Hitzler</surname><given-names>JK</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name><name><surname>Buchwald</surname><given-names>M</given-names></name></person-group><article-title>Short-term granulocyte colony-stimulating factor and erythropoietin treatment enhances hematopoiesis and survival in the mitomycin C-conditioned Fancc(-/-) mouse model, while long-term treatment is ineffective</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>1499</fpage><lpage>1501</lpage><pub-id pub-id-type="pmid">12149239</pub-id><pub-id pub-id-type="doi">10.1182/blood-2001-11-0007</pub-id></citation></ref><ref id="B123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Titus</surname><given-names>TA</given-names></name><name><surname>Selvig</surname><given-names>DR</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Starks</surname><given-names>AM</given-names></name><name><surname>Roe</surname><given-names>BA</given-names></name><name><surname>Postlethwait</surname><given-names>JH</given-names></name></person-group><article-title>The Fanconi anemia gene network is conserved from zebrafish to human</article-title><source>Gene</source><year>2006</year><volume>371</volume><fpage>211</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">16515849</pub-id><pub-id pub-id-type="doi">10.1016/j.gene.2005.11.038</pub-id></citation></ref><ref id="B124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobeck</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>S</given-names></name><name><surname>Costanzo</surname><given-names>V</given-names></name><name><surname>de Graaf</surname><given-names>B</given-names></name><name><surname>Reuter</surname><given-names>T</given-names></name><name><surname>de Winter</surname><given-names>J</given-names></name><name><surname>Wallisch</surname><given-names>M</given-names></name><name><surname>Akkari</surname><given-names>Y</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks</article-title><source>Mol Cell Biol</source><year>2006</year><volume>26</volume><fpage>425</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">16382135</pub-id><pub-id pub-id-type="doi">10.1128/MCB.26.2.425-437.2006</pub-id></citation></ref><ref id="B125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marek</surname><given-names>LR</given-names></name><name><surname>Bale</surname><given-names>AE</given-names></name></person-group><article-title>Drosophila homologs of FANCD2 and FANCL function in DNA repair</article-title><source>DNA Repair (Amst)</source><year>2006</year><volume>5</volume><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">16860002</pub-id><pub-id pub-id-type="doi">10.1016/j.dnarep.2006.05.044</pub-id></citation></ref><ref id="B126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collis</surname><given-names>SJ</given-names></name><name><surname>Barber</surname><given-names>LJ</given-names></name><name><surname>Ward</surname><given-names>JD</given-names></name><name><surname>Martin</surname><given-names>JS</given-names></name><name><surname>Boulton</surname><given-names>SJ</given-names></name></person-group><article-title>C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair</article-title><source>DNA Repair (Amst)</source><year>2006</year><volume>5</volume><fpage>1398</fpage><lpage>1406</lpage><pub-id pub-id-type="pmid">16914393</pub-id><pub-id pub-id-type="doi">10.1016/j.dnarep.2006.06.010</pub-id></citation></ref><ref id="B127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>TX</given-names></name><name><surname>Howlett</surname><given-names>NG</given-names></name><name><surname>Deng</surname><given-names>M</given-names></name><name><surname>Langenau</surname><given-names>DM</given-names></name><name><surname>Hsu</surname><given-names>K</given-names></name><name><surname>Rhodes</surname><given-names>J</given-names></name><name><surname>Kanki</surname><given-names>JP</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name></person-group><article-title>Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis</article-title><source>Dev Cell</source><year>2003</year><volume>5</volume><fpage>903</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">14667412</pub-id><pub-id pub-id-type="doi">10.1016/S1534-5807(03)00339-3</pub-id></citation></ref><ref id="B128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chirnomas</surname><given-names>D</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>de la Vega</surname><given-names>M</given-names></name><name><surname>Vaidya</surname><given-names>AP</given-names></name><name><surname>Vasserman</surname><given-names>M</given-names></name><name><surname>Hartman</surname><given-names>AR</given-names></name><name><surname>Kennedy</surname><given-names>R</given-names></name><name><surname>Foster</surname><given-names>R</given-names></name><name><surname>Mahoney</surname><given-names>J</given-names></name><name><surname>Seiden</surname><given-names>MV</given-names></name><etal></etal></person-group><article-title>Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway</article-title><source>Mol Cancer Ther</source><year>2006</year><volume>5</volume><fpage>952</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">16648566</pub-id><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0493</pub-id></citation></ref><ref id="B129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>JK</given-names></name><name><surname>Hsu</surname><given-names>MM</given-names></name><name><surname>Ho</surname><given-names>YF</given-names></name><name><surname>Shen</surname><given-names>TS</given-names></name><name><surname>Ko</surname><given-names>JY</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Lin</surname><given-names>BR</given-names></name><name><surname>Ming-Shiang</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions</article-title><source>Anticancer Res</source><year>2001</year><volume>21</volume><fpage>2895</fpage><lpage>2900</lpage><pub-id pub-id-type="pmid">11712783</pub-id></citation></ref><ref id="B130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Jeffrey</surname><given-names>PD</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Kinnucan</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Thoma</surname><given-names>NH</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>PL</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><article-title>BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>1837</fpage><lpage>1848</lpage><pub-id pub-id-type="pmid">12228710</pub-id><pub-id pub-id-type="doi">10.1126/science.297.5588.1837</pub-id></citation></ref><ref id="B131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kowal</surname><given-names>P</given-names></name><name><surname>Gurtan</surname><given-names>AM</given-names></name><name><surname>Stuckert</surname><given-names>P</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Ellenberger</surname><given-names>T</given-names></name></person-group><article-title>Structural determinants of human fancf protein that function in the assembly of a DNA damage signaling complex</article-title><source>J Biol Chem</source><year>2006</year><comment>on line publication</comment><pub-id pub-id-type="pmid">17082180</pub-id></citation></ref><ref id="B132"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudolf</surname><given-names>J</given-names></name><name><surname>Makrantoni</surname><given-names>V</given-names></name><name><surname>Ingledew</surname><given-names>WJ</given-names></name><name><surname>Stark</surname><given-names>MJ</given-names></name><name><surname>White</surname><given-names>MF</given-names></name></person-group><article-title>The DNA repair helicases XPD and FancJ have essential iron-sulfur domains</article-title><source>Mol Cell</source><year>2006</year><volume>23</volume><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">16973432</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2006.07.019</pub-id></citation></ref><ref id="B133"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Timmers</surname><given-names>C</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Hejna</surname><given-names>J</given-names></name><name><surname>Reifsteck</surname><given-names>C</given-names></name><name><surname>Lucas</surname><given-names>L</given-names></name><name><surname>Bruun</surname><given-names>D</given-names></name><name><surname>Thayer</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>B</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><etal></etal></person-group><article-title>Positional cloning of a novel Fanconi anemia gene, FANCD2</article-title><source>Mol Cell</source><year>2001</year><volume>7</volume><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">11239453</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00172-1</pub-id></citation></ref><ref id="B134"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination</article-title><source>Cell Cycle</source><year>2004</year><volume>3</volume><fpage>179</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">14712086</pub-id></citation></ref><ref id="B135"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JS</given-names></name><name><surname>Winkelmann</surname><given-names>N</given-names></name><name><surname>Petalcorin</surname><given-names>MI</given-names></name><name><surname>McIlwraith</surname><given-names>MJ</given-names></name><name><surname>Boulton</surname><given-names>SJ</given-names></name></person-group><article-title>RAD-51-dependent and -independent roles of a Caenorhabditis elegans BRCA2-related protein during DNA double-strand break repair</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><fpage>3127</fpage><lpage>3139</lpage><pub-id pub-id-type="pmid">15798199</pub-id><pub-id pub-id-type="doi">10.1128/MCB.25.8.3127-3139.2005</pub-id></citation></ref><ref id="B136"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leveille</surname><given-names>F</given-names></name><name><surname>Blom</surname><given-names>E</given-names></name><name><surname>Medhurst</surname><given-names>AL</given-names></name><name><surname>Bier</surname><given-names>P</given-names></name><name><surname>Laghmani el</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Rooimans</surname><given-names>MA</given-names></name><name><surname>Sobeck</surname><given-names>A</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>The Fanconi anemia gene product FANCF is a flexible adaptor protein</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>39421</fpage><lpage>39430</lpage><pub-id pub-id-type="pmid">15262960</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M407034200</pub-id></citation></ref><ref id="B137"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciccia</surname><given-names>A</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Coulthard</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>Laghmani el</surname><given-names>H</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>McDonald</surname><given-names>N</given-names></name><name><surname>de Winter</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>Identification of FAAP24, a Fanconi Anemia Core Complex Protein that Interacts with FANCM</article-title><source>Mol Cell</source><year>2007</year><volume>25</volume><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">17289582</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2007.01.003</pub-id></citation></ref></ref-list></back></article>


